NEO: Company disclosure · Other company developments

Item 7.01 Regulation FD Disclosure. On June 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below. The information in Item 7.01 of this Current Report and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 8.01 Other Events. As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021. On June 20, 2026, the Company finalized a civil settlement with the U.S. Department of Justice (“DOJ”), acting on behalf of the OIG-HHS, resolving the U.S. government’s investigation concerning consulting services provided by the Company to certain health care providers, as described above. Pursuant to the terms of the settlement agreement, the Company has agreed to pay $9,813,260 to resolve the matter. As previously disclosed, as of March 31, 2026, the Company had accrued a reserve of $11.2 million for potential damages and liabilities associated with the matters identified during the course of the investigation. The settlement agreement is neither